Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients: phase I toxicity and effects on lipid metabolism.
Year: 1988
Type: article
Study design: Clinical Trial
Source: Journal of Clinical Oncology
Institution: Dana-Farber Cancer Institute
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W1884955980